Search
NextCure Inc
NXTCAdd to Watchlist
1.600USD
-0.150-8.57%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
5.78MMarket Cap
LossP/E TTM
More Details of NextCure Inc Company
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
NextCure Inc Info
Ticker SymbolNXTC
Company nameNextCure Inc
IPO dateMay 09, 2019
CEORichman (Michael S)
Number of employees43
Security typeOrdinary Share
Fiscal year-endMay 09
Address9000 Virginia Manor Rd Ste 200
CityBELTSVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20705-4214
Phone12403994900
Websitehttps://www.nextcure.com/
Ticker SymbolNXTC
IPO dateMay 09, 2019
CEORichman (Michael S)
Company Executives of NextCure Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.52K
+2.33%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Mr. Steven P. Cobourn, CPA
Mr. Steven P. Cobourn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Sourav Kundu, Ph.D.
Dr. Sourav Kundu, Ph.D.
Senior Vice President - Development and Manufacturing
Senior Vice President - Development and Manufacturing
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.52K
+2.33%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Mr. Steven P. Cobourn, CPA
Mr. Steven P. Cobourn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of NextCure Inc?
The top five shareholders of NextCure Inc are: Mr. Michael Richman
How many institutions hold shares of NextCure Inc (NXTC)?
As of 2026Q1, 79 institutions hold shares of NextCure Inc, with a combined market value of approximately 1.75M, accounting for 48.41% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 214940.00.